This page shows the latest enzalutamide news and features for those working in and with pharma, biotech and healthcare.
Pfizer/Astellas’ prostate cancer treatment Xtandi (enzalutamide) is also a prominent market competitor, with approvals in nmCRPC, mCSPC and metastatic castration-resistant prostate cancer (mCRPC).
In the key secondary endpoint of overall survival, Lynparza reduced the risk of death by 31% compared to enzalutamide or abiraterone. ... Lynparza is the only PARP inhibitor to demonstrate overall survival versus enzalutamide or abiraterone for men with
Astellas’ Xtandi (enzalutamide).
Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with J&J’s Erleada (apalutamide), as well as Pfizer/Astellas’ Xtandi (enzalutamide).
Erleada can now be used for mCSPC patients in combination with ADT in Europe ahead of Xtandi (enzalutamide), which was approved for this indication in December in the US but still
Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).
More from news
Approximately 12 fully matching, plus 59 partially matching documents found.
The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.
The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
No results were found
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...